Form 4: Tourmaline Bio Director and 10% Owner Clay B. Siegall Granted 16,800 Stock Options

Tourmaline Bio, Inc. Director and 10% Owner Clay B. Siegall was granted 16,800 stock options with an exercise price of $18.73, vesting on the earlier of June 4, 2026, or the 2026 Annual Meeting of Stockholders.

Summary

• Clay B. Siegall, a Director and 10% Owner of Tourmaline Bio, Inc. (TRML), was granted 16,800 stock options.
• The transaction date for this grant was June 4, 2025.
• The exercise price for these options is $18.73 per share.
• The options will vest 100% on the earlier of the anniversary of the transaction date (June 4, 2026) or the date of the Issuer's 2026 Annual Meeting of Stockholders, contingent on Mr. Siegall's continued service.
• The options have an expiration date of June 4, 2035.
• Following this transaction, Mr. Siegall beneficially owns 16,800 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive signal of alignment between management and shareholders, but it is a routine compensation event and does not indicate significant new positive or negative company performance.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance and value creation.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing details a routine insider transaction involving the grant of stock options to a director, which is a common practice in the biotechnology and broader corporate sectors to incentivize executive and director performance and align their interests with shareholders. It does not provide broader industry-specific context or trends.

Related Party Transactions

• The stock option grant to Clay B. Siegall, a Director and 10% Owner, constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The option grant aligns the director's interests with shareholders, potentially leading to better long-term performance and value creation.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• Continued service of Clay B. Siegall on the board for the options to vest.
• Potential exercise of options by Clay B. Siegall upon vesting and favorable stock price movement.

Key Dates

Recommendation

Keywords

Tourmaline Bio, TRML, Clay B. Siegall, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Biotechnology